Bevacizumab/paclitaxelDysphonia: 4 case reports

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2014年 / 1518卷 / 1期

关键词：

D O I：

10.1007/s40278-014-3299-7

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：47 / 47

相关论文

共 50 条

[1] Bevacizumab/pazopanibVarious toxicities: 4 case reports
Reactions Weekly, 2019, 1758 (1) : 79 - 79
[2] Aflibercept/bevacizumab/ranibizumabEndophthalmitis: 4 case reports
Reactions Weekly, 2023, 1952 (1) : 34 - 34
[3] Bevacizumab/paclitaxelVarious toxicities: 4 case reports
Reactions Weekly, 2021, 1844 (1) : 94 - 94
[4] Bevacizumab/irinotecanVarious toxicities: 4 case reports
Reactions Weekly, 2014, 1532 (1) : 54 - 54
[5] Bevacizumab/temozolomideLack of efficacy: 4 case reports
Reactions Weekly, 2023, 1940 (1) : 114 - 114
[6] Bevacizumab/nicorandilVarious toxicities: 4 case reports
Reactions Weekly, 2018, 1729 (1) : 52 - 52
[7] Bevacizumab/irinotecanVarious toxicities: 4 case reports
Reactions Weekly, 2016, 1612 (1) : 36 - 36
[8] Bevacizumab/capecitabineVarious toxicities: 4 case reports
Reactions Weekly, 2018, 1733 (1) : 83 - 83
[9] Bevacizumab/temozolomideVarious toxicities: 4 case reports
Reactions Weekly, 2017, 1660 (1) : 83 - 83
[10] Bevacizumab/ranibizumab/verteporfinGeographic atrophy: 4 case reports
Reactions Weekly, 2015, 1536 (1) : 49 - 49

← 1 2 3 4 5 →